Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Expanded_access × dodecyl maltoside × 30 days × Clear all

Status

Sponsor Class

Study Type

Interventional 1 Expanded_access 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urologic Neoplasms 1 Urinary Bladder Neoplasms 1 Non-Muscle Invasive Bladder Neoplasms 1 Carcinoma, Transitional Cell 1

Interventions

selinexor 1 mifamurtide 1 futibatinib 1 dodecyl maltoside 1 capmatinib 1 Sunitinib 1 Eflornithine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06443944 2026-03-06

An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG

CG Oncology, Inc.

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡